Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Weisova P ^a,b   Alvarez, S P ^a,c   Kilbride, S M ^a   Anilkumar, U ^a   Baumann, B ^a   Jordan J ^c   Bernas, T ^a,d   Huber, H J ^a   Dussmann H ^a   Prehn, J H M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

AMP activated protein kinase; bioenergetics; Ca2+ homeostasis; glutamate excitotoxicity; mitochondria; plasma membrane potential

Indexed keywords

DIMEBON; GLUCOSE TRANSPORTER 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ADENOSINE TRIPHOSPHATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; GLUTAMIC ACID; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM SIGNALING; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE SILENCING; HYPERPOLARIZATION; MEMBRANE TRANSPORT; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NERVE CELL EXCITABILITY; NEUROPROTECTION; NONHUMAN; RAT; ANIMAL; CEREBELLUM; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; MEMBRANE POTENTIAL; METABOLISM; MITOCHONDRION; NEOCORTEX; NERVE CELL;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CEREBELLUM; GENE SILENCING; GLUCOSE TRANSPORTER TYPE 3; GLUTAMIC ACID; INDOLES; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; NEOCORTEX; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PROTEIN-SERINE-THREONINE KINASES; RATS;

EID: 84886819811     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.92     Document Type: Article

References (51)

1. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-Daspartate receptor antagonism. J Pharmacol Exp Ther 2010 333: 748-757.
2. Vignisse J, Steinbusch HW, Bolkunov A, Nunes J, Santos AI, Grandfils C et al. Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011 35: 510-522.
3. Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry Jr. AV, Buccafusco JJ. The acute effects of dimebolin, a potential Alzheimers disease treatment, on working memory in rhesus monkeys. Br J Pharmacol 2011 164: 970-978.
4. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimers disease: a randomised, double-blind, placebo-controlled study. Lancet 2008 372: 207-215. (Pubitemid 351978110)
5. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 2010 21: 389-402.
6. Moreira PI, Zhu X, Wang X, Lee HG, Nunomura A, Petersen RB et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010 1802: 212-220.
7. Miller G. Pharmacology. The puzzling rise and fall of a dark-horse Alzheimers drug. Science 2010 327: 1309.
8. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010 2: 25.
9. Naga KK, Geddes JW. Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 2011 13: 31-36.
10. Weisova P, Concannon CG, Devocelle M, Prehn JH, Ward MW. Regulation of glucose transporter 3 surface expression by the AMP-activated protein kinase mediates tolerance to glutamate excitation in neurons. J Neurosci 2009 29: 2997-3008.
11. Ward MW, Rego AC, Frenguelli BG, Nicholls DG. Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells. J Neurosci 2000 20: 7208-7219.
12. Concannon CG, Tuffy LP, Weisova P, Bonner HP, Davila D, Bonner C et al. AMP kinase-mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis. J Cell Biol 2010 189: 83-94.
13. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988 1: 623-634.
14. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986 19: 105-111. (Pubitemid 16114163)
15. Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008 71: 1862-1868.
16. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009 30: 379-387.
17. Ward MW, Huber HJ, Weisova P, Dussmann H, Nicholls DG, Prehn JH. Mitochondrial and plasma membrane potential of cultured cerebellar neurons during glutamate-induced necrosis, apoptosis, and tolerance. J Neurosci 2007 27: 8238-8249. (Pubitemid 47219629)
18. Ward MW, Kushnareva Y, Greenwood S, Connolly CN. Cellular and subcellular calcium accumulation during glutamate-induced injury in cerebellar granule neurons. J Neurochem 2005 92: 1081-1090. (Pubitemid 40344299)
19. Ward MW, Rehm M, Duessmann H, Kacmar S, Concannon CG, Prehn JH. Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 2006 281: 5837-5844. (Pubitemid 43847683)
20. Concannon CG, Ward MW, Bonner HP, Kuroki K, Tuffy LP, Bonner CT et al. NMDA receptor-mediated excitotoxic neuronal apoptosis in vitro and in vivo occurs in an ER stress and PUMA independent manner. J Neurochem 2008 105: 891-903. (Pubitemid 351565712)
21. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003 993: 334-344, discussion 345-349. (Pubitemid 36808462)
22. Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid-beta induced impairments of mitochondrial form and function. J Alzheimers Dis 2012 31: 21-32.
23. Nicholls DG, Ward MW. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 2000 23: 166-174. (Pubitemid 30151213)
24. Krohn AJ, Wahlbrink T, Prehn JH. Mitochondrial depolarization is not required for neuronal apoptosis. J Neurosci 1999 19: 7394-7404. (Pubitemid 29404596)
25. Dussmann H, Rehm M, Kogel D, Prehn JH. Outer mitochondrial membrane permeabilization during apoptosis triggers caspase-independent mitochondrial and caspase-dependent plasma membrane potential depolarization: a single-cell analysis. J Cell Sci 2003 116(Pt 3): 525-536. (Pubitemid 36231292)
26. Freedman JC, Novak TS. Optical measurement of membrane potential in cells, organelles, and vesicles. Methods Enzymol 1989 172: 102-122. (Pubitemid 19170349)
27. Weisova P, Anilkumar U, Ryan C, Concannon CG, Prehn JH, Ward W. Mild mitochondrial uncoupling induced protection against neuronal excitotoxicity requires AMPK activity. Biochim Biophys Acta 2012 1817: 744-753.
28. Weisova P, Davila D, Tuffy LP, Ward MW, Concannon CG, Prehn JH. Role of 50-adenosine monophosphate-activated protein kinase in cell survival and death responses in neurons. Antioxid Redox Signal 2011 14: 1863-1876.
29. Ikematsu N, Dallas ML, Ross FA, Lewis RW, Rafferty JN, David JA et al. Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability. Proc Natl Acad Sci USA 2011 108: 18132-18137.
30. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM et al. Calmodulindependent protein kinase kinase-beta is an alternative upstream kinase for AMPactivated protein kinase. Cell Metab 2005 2: 9-19. (Pubitemid 43239821)
31. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR et al. Ca2/calmodulin-dependent protein kinase kinase-beta acts upstream of AMPactivated protein kinase in mammalian cells. Cell Metab 2005 2: 21-33. (Pubitemid 43239822)
32. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003 13: 2004-2008. (Pubitemid 37425212)
33. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 108: 1167-1174. (Pubitemid 32995375)
34. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011 13: 132-141.
35. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987 7: 369-379. (Pubitemid 17017466)
36. Ascher P, Nowak L. A patch-clamp study of excitatory amino acid activated channels. Adv Exp Med Biol 1986 203: 507-511.
37. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996 67: 2282-2291. (Pubitemid 26392497)
38. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M et al. Preclinical study of dimebon on beta-amyloid-mediated neuropathology in Alzheimers disease. Mol Neurodegener 2011 6: 7.
39. Day M, Chandran P, Luo F, Rustay NR, Markosyan S, LeBlond D et al. Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. Neuroscience 2011 189: 299-304.
40. Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. J Cereb Blood Flow Metab 2012 32: 1222-1232.
41. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007 8: 621-632. (Pubitemid 46785060)
42. Culmsee C, Monnig J, Kemp BE, Mattson MP. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 2001 17: 45-58. (Pubitemid 32928285)
43. Davila D, Connolly NM, Bonner H, Weisova P, Dussmann H, Concannon CG et al. Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate. Cell Death Differ 2012 19: 1677-1688.
44. Kilbride SM, Farrelly AM, Bonner C, Ward MW, Nyhan KC, Concannon CG et al. AMP-activated protein kinase mediates apoptosis in response to bioenergetic stress through activation of the pro-apoptotic Bcl-2 homology domain-3-only protein BMF. J Biol Chem 2010 285: 36199-36206.
45. McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem 2005 280: 20493-20502. (Pubitemid 40776749)
46. Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, Kang JJ et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntingtons disease. J Cell Biol 2011 194: 209-227.
47. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH et al. Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry 2013 18: 882-888.
48. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimers mouse model. Mol Psychiatry 2013 18: 889-897.
49. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet 2009 18: 4153-4170.
50. Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimers disease and other tauopathies. Acta Neuropathol 121: 337-349.
51. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004 101: 3329-3335. (Pubitemid 38338195)